SELLAS Life Sciences (SLS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

SLS · Stock Price

USD 4.93+3.37 (+216.03%)

Market Cap: $911.4M

Historical price data

Market Cap: $911.4MPipeline: 8 drugs (1 Phase 3)HQ: New York, United States

Sector Ranking#20 in Immunotherapy / Immuno-Oncology #49 in Oncology (General)

Overview

SELLAS Life Sciences is a clinical-stage biotech focused on developing transformative cancer therapies, with a mission centered on high-unmet-need oncology indications. Its strategy leverages two core platforms: a WT1-targeting peptide vaccine (GPS) and a highly selective CDK9 inhibitor (SLS009), both supported by strong clinical data and strategic partnerships. The company is approaching a pivotal inflection point with the final analysis of its Phase 3 REGAL trial in AML expected in 2026, backed by a strengthened balance sheet from recent warrant exercises.

OncologyHematology

Technology Platform

Two complementary platforms: 1) A peptide-based cancer vaccine technology targeting the WT1 antigen to generate T-cell immunity, and 2) A highly selective small molecule CDK9 inhibition platform designed to suppress key cancer survival pathways.

Pipeline

8

8 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Galinpepimut-S + Azacitidine + Venetoclax + Decitabine + Cyt...	Acute Myeloid Leukemia	Phase 3
Galinpepimut-S + GM-CSF	Acute Myeloid Leukemia	Phase 2
Herceptin + NeuVax vaccine + GM-CSF	Breast Cancer	Phase 2
Galinpepimut-S + Montanide + GM-CSF + Montanide + GM-CSF	Malignant Pleural Mesothelioma	Phase 2
NeuVax vaccine + Trastuzumab + GM-CSF	Breast Cancer	Phase 2

Funding History

3

Total raised:$80M

PIPE$40MBVF PartnersMar 15, 2022

PIPE$25MPerceptive AdvisorsDec 15, 2020

IPO$15MUndisclosedFeb 14, 2018

Opportunities

The primary opportunity lies in the potential approval of GPS as a first-in-class maintenance immunotherapy for AML patients in second remission, a setting with no standard of care.

For SLS009, success in frontline AML patients resistant to standard therapy could position it as a cornerstone combination agent in a multi-billion dollar market.

Risk Factors

Key risks include clinical failure of the pivotal Phase 3 REGAL trial, regulatory challenges for a novel vaccine modality, intense competition in the AML and CDK9 inhibitor spaces, and the eventual need for partnership or commercial build-out given the company's virtual model.

Competitive Landscape

SELLAS competes in the crowded AML and CDK9 inhibitor markets. GPS's niche in post-remission maintenance and SLS009's focus on venetoclax resistance and use of predictive biomarkers are key differentiators. Success hinges on demonstrating superior efficacy and/or safety profiles compared to other immunotherapies and targeted agents in development.